Actinic Keratosis Treatment Market by Drug Type (Fluorouracil, Imiquimod, Diclofenac, and Others), Type (Prescription and OTC), and Distribution Channel (Hospital Pharmacies, Drug Stores & Retail Pharmacies, and Online Providers): Global Opportunity Analysis and Industry Forecast, 2019–2026
- ALL3815889
- 235 Pages
- February 2020
- Medical Devices
Actinic keratosis (AK) is the most common precancer that forms on skin damaged by chronic exposure to ultraviolet (UV) rays from the sun or indoor tanning characterized by rough, scaly patch on skin. It is most commonly found on face, lips, ears, back of your hands, forearms, scalp, or neck. Different types of treatment options available for the treatment of actinic keratosis include cryotherapy, photodynamic therapy, topical medications, and combination therapy. Drugs such as fluorouracil, imiquimod, diclofenac, ingenol mebutate, and others have been approved for the treatment of actinic keratosis.
Significant increase in prevalence of actinic keratosis, use of topical therapeutics as a first line treatment option, rise in demand for actinic keratosis therapeutics, strong presence of pipeline drugs, and rise in geriatric population are the key factors that fuel the growth of the actinic keratosis treatment market. Moreover, rise in adoption of actinic keratosis treatment medications, increase in R&D for the innovation of new products, and surge in healthcare awareness toward actinic keratosis treatment are other factors that contribute toward the growth of the market. However, availability of alternate therapies for treatment of actinic keratosis can hamper the market growth.
The actinic keratosis treatment market is segmented on the basis of drug type, type, distribution channel, and region. By drug type, the market is categorized into fluorouracil, imiquimod, diclofenac, and others. On the basis of type, the market is bifurcated into prescription and OTC. According to distribution channel, the market is divided into hospital pharmacies, drug stores & retail pharmacies, and online providers. Based on region, the market is studied across North America (the U.S., Canada, and Mexico), Europe (Germany, France, the UK, and rest of Europe), Asia-Pacific (China, Japan, Australia, and rest of Asia-Pacific), and LAMEA (Brazil, Saudi Arabia, South Africa, and rest of LAMEA).
KEY BENEFITS FOR STAKEHOLDERS
• The study provides an in-depth analysis of the market along with the current trends and future estimations to elucidate the imminent investment pockets.
• It offers a quantitative analysis from 2018 to 2026, which is expected to enable the stakeholders to capitalize on the prevailing market opportunities.
• A comprehensive analysis of all the geographical regions is provided to determine the existing opportunities.
• The profiles and growth strategies of the key players are thoroughly analyzed to understand the competitive outlook of the global market.
KEY MARKET SEGMENTS
By Drug Type
• Fluorouracil
• Imiquimod
• Diclofenac
• Others
By Type
• Prescription
• OTC
Distribution Channel
• Hospital Pharmacies
• Drug Stores & Retail Pharmacies
• Online Providers
By Region
• North America
o U.S.
o Canada
o Mexico
• Europe
o Germany
o France
o UK
o Italy
o Spain
o Rest of Europe
• Asia-Pacific
o Japan
o China
o Australia
o Rest of Asia-Pacific
• LAMEA
o Brazil
o Saudi Arabia
o South Africa
o Rest of LAMEA
LIST OF KEY PLAYERS PROFILED IN THE REPORT
• 3M Company
• Almirall, S.A.
• Bausch Health Companies Inc.
• Biofrontera, Inc.
• Hill Dermaceuticals, Inc.
• LEO Pharma A/S
• Mylan N.V
• Novartis AG
• Stanford Chemicals
• Sun Pharmaceutical Industries Ltd. (DUSA Pharmaceuticals, Inc.)
LIST OF OTHER PLAYERS IN THE VALUE CHAIN (These players are not profiled in the report. The same will be included on request.)
• Nestlé S.A.
1.1. Report description
1.2. Key Benefits for Stakeholders
1.3. Key market segments
1.3.1. List of key players profiled in the report
1.4. Research methodology
1.4.1. Secondary research
1.4.2. Primary research
1.4.3. Analyst tools and models
CHAPTER 2: EXECUTIVE SUMMARY
2.1. Key findings of the study
2.2. CXO perspective
CHAPTER 3: MARKET OVERVIEW
3.1. Market definition and scope
3.2. Key findings
3.2.1. Top investment pockets
3.2.2. Market player positioning, 2018
3.3. Porter’s five force analysis
3.4. Market dynamics
3.4.1. Drivers
3.4.1.1. Rise in prevalence of actinic keratosis
3.4.1.2. Potential drugs present in pipeline
3.4.1.3. Increase in government expenditure on healthcare
3.4.2. Restraint
3.4.2.1. Availability of alternate treatment options
3.4.3. Opportunities
3.4.3.1. Growth opportunities in emerging markets
3.4.4. Impact analysis
CHAPTER 4: ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE
4.1. Overview
4.1.1. Market size and forecast
4.2. Fluorouracil
4.2.1. Key market trends, growth factors, and opportunities
4.2.2. Market size and forecast, by region
4.2.3. Market analysis, by country
4.3. Imiquimod
4.3.1. Key market trends, growth factors, and opportunities
4.3.2. Market size and forecast
4.3.3. Market analysis, by country
4.4. Diclofenac
4.4.1. Key market trends, growth factors, and opportunities
4.4.2. Market size and forecast
4.4.3. Market analysis, by country
4.5. Others
4.5.1. Key market trends, growth factors, and opportunities
4.5.2. Market size and forecast
4.5.3. Market analysis, by country
CHAPTER 5: ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE
5.1. Overview
5.1.1. Market size and forecast
5.2. Prescription
5.2.1. Market size and forecast, by region
5.2.2. Market analysis, by country
5.3. OTC
5.3.1. Market size and forecast, by region
5.3.2. Market analysis, by country
CHAPTER 6: ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL
6.1. Overview
6.1.1. Market size and forecast
6.2. Hospitals pharmacies
6.2.1. Market size and forecast
6.2.2. Market analysis, by country
6.3. Drug stores and retail pharmacies
6.3.1. Market size and forecast
6.3.2. Market analysis, by country
6.4. Online providers
6.4.1. Market size and forecast
6.4.2. Market analysis, by country
CHAPTER 7: ACTINIC KERATOSIS TREATMENT MARKET, BY REGION
7.1. Overview
7.1.1. Market size and forecast
7.2. North America
7.2.1. Key market trends, growth factors, and opportunities
7.2.2. Market size and forecast, by country
7.2.2.1. U.S.
7.2.2.1.1. U.S. actinic keratosis treatment market, by drug type
7.2.2.1.2. U.S. actinic keratosis treatment market, by type
7.2.2.1.3. U.S. actinic keratosis treatment market, by distribution channel
7.2.2.2. Canada
7.2.2.2.1. Canada actinic keratosis treatment market, by drug type
7.2.2.2.2. Canada actinic keratosis treatment market, by type
7.2.2.2.3. Canada actinic keratosis treatment market, by distribution channel
7.2.2.3. Mexico
7.2.2.3.1. Mexico actinic keratosis treatment market, by drug type
7.2.2.3.2. Mexico actinic keratosis treatment market, by type
7.2.2.3.3. Mexico actinic keratosis treatment market, by distribution channel
7.2.3. North America market size and forecast, by drug type
7.2.4. North America actinic keratosis treatment market, by type
7.2.5. North America actinic keratosis treatment market, by distribution channel
7.3. Europe
7.3.1. Key market trends, growth factors, and opportunities
7.3.2. Market size and forecast, by country
7.3.2.1. Germany
7.3.2.1.1. Germany actinic keratosis treatment market, by drug type
7.3.2.1.2. Germany actinic keratosis treatment market, by type
7.3.2.1.3. Germany actinic keratosis treatment market, by distribution channel
7.3.2.2. France
7.3.2.2.1. France actinic keratosis treatment market, by drug type
7.3.2.2.2. France actinic keratosis treatment market, by type
7.3.2.2.3. France actinic keratosis treatment market, by distribution channel
7.3.2.3. UK
7.3.2.3.1. UK actinic keratosis treatment market, by drug type
7.3.2.3.2. UK actinic keratosis treatment market, by type
7.3.2.3.3. UK actinic keratosis treatment market, by distribution channel
7.3.2.4. Italy
7.3.2.4.1. Italy actinic keratosis treatment market, by drug type
7.3.2.4.2. Italy actinic keratosis treatment market, by type
7.3.2.4.3. Italy actinic keratosis treatment market, by distribution channel
7.3.2.5. Spain
7.3.2.5.1. Spain actinic keratosis treatment market, by drug type
7.3.2.5.2. Spain actinic keratosis treatment market, by type
7.3.2.5.3. Spain actinic keratosis treatment market, by distribution channel
7.3.2.6. Rest of Europe
7.3.2.6.1. Rest of Europe actinic keratosis treatment market, by drug type
7.3.2.6.2. Rest of Europe actinic keratosis treatment market, by type
7.3.2.6.3. Rest of Europe actinic keratosis treatment market, by distribution channel
7.3.3. Europe market size and forecast, by drug type
7.3.4. Europe actinic keratosis treatment market, by type
7.3.5. Europe actinic keratosis treatment market, by distribution channel
7.4. Asia-Pacific
7.4.1. Key market trends, growth factors, and opportunities
7.4.2. Market size and forecast, by country
7.4.2.1. Japan
7.4.2.1.1. Japan actinic keratosis treatment market, by drug type
7.4.2.1.2. Japan actinic keratosis treatment market, by type
7.4.2.1.3. Japan actinic keratosis treatment market, by distribution channel
7.4.2.2. China
7.4.2.2.1. China actinic keratosis treatment market, by drug type
7.4.2.2.2. China actinic keratosis treatment market, by type
7.4.2.2.3. China actinic keratosis treatment market, by distribution channel
7.4.2.3. Australia
7.4.2.3.1. Australia actinic keratosis treatment market, by drug type
7.4.2.3.2. Australia actinic keratosis treatment market, by type
7.4.2.3.3. Australia actinic keratosis treatment market, by distribution channel
7.4.2.4. Rest of Asia-Pacific
7.4.2.4.1. Rest of Asia-Pacific actinic keratosis treatment market, by drug type
7.4.2.4.2. Rest of Asia-Pacific actinic keratosis treatment market, by type
7.4.2.4.3. Rest of Asia-Pacific actinic keratosis treatment market, by distribution channel
7.4.3. Asia-Pacific market size and forecast, by drug type
7.4.4. Asia-Pacific actinic keratosis treatment market, by type
7.4.5. Asia-Pacific actinic keratosis treatment market, by distribution channel
7.5. LAMEA
7.5.1. Key market trends, growth factors, and opportunities
7.5.2. Market size and forecast, by country
7.5.2.1. Brazil
7.5.2.1.1. Brazil actinic keratosis treatment market, by drug type
7.5.2.1.2. Brazil actinic keratosis treatment market, by type
7.5.2.1.3. Brazil actinic keratosis treatment market, by distribution channel
7.5.2.2. Saudi Arabia
7.5.2.2.1. Saudi Arabia actinic keratosis treatment market, by drug type
7.5.2.2.2. Saudi Arabia actinic keratosis treatment market, by type
7.5.2.2.3. Saudi Arabia actinic keratosis treatment market, by distribution channel
7.5.2.3. South Africa
7.5.2.3.1. South Africa actinic keratosis treatment market, by drug type
7.5.2.3.2. South Africa actinic keratosis treatment market, by type
7.5.2.3.3. South Africa actinic keratosis treatment market, by distribution channel
7.5.2.4. Rest of LAMEA
7.5.2.4.1. Rest of LAMEA actinic keratosis treatment market, by drug type
7.5.2.4.2. Rest of LAMEA actinic keratosis treatment market, by type
7.5.2.4.3. Rest of LAMEA actinic keratosis treatment market, by distribution channel
7.5.3. LAMEA market size and forecast, by drug type
7.5.4. LAMEA actinic keratosis treatment market, by type
7.5.5. LAMEA actinic keratosis treatment market, by distribution channel
CHAPTER 8: COMPANY PROFILES
8.1. 3M Company
8.1.1. Company overview
8.1.2. Company snapshot
8.1.3. Operating business segments
8.1.4. Product portfolio
8.1.5. Business performance
8.2. Almirall, S.A.
8.2.1. Company overview
8.2.2. Company snapshot
8.2.3. Operating business segments
8.2.4. Product portfolio
8.2.5. Business performance
8.2.6. Key strategic moves and developments
8.3. Bausch Health Companies Inc.
8.3.1. Company overview
8.3.2. Company snapshot
8.3.3. Operating business segments
8.3.4. Product portfolio
8.3.5. Business performance
8.4. Biofrontera, Inc.
8.4.1. Company overview
8.4.2. Company snapshot
8.4.3. Operating business segments
8.4.4. Product portfolio
8.4.5. Business performance
8.4.6. Key strategic moves and developments
8.5. Hill Dermaceuticals, Inc.
8.5.1. Company overview
8.5.2. Company snapshot
8.5.3. Operating business segments
8.5.4. Product portfolio
8.5.5. Key strategic moves and developments
8.6. LEO Pharma A/S
8.6.1. Company overview
8.6.2. Company snapshot
8.6.3. Operating business segments
8.6.4. Product portfolio
8.6.5. Business performance
8.7. Mylan N.V
8.7.1. Company overview
8.7.2. Company snapshot
8.7.3. Operating business segments
8.7.4. Product portfolio
8.7.5. Business performance
8.8. Novartis AG
8.8.1. Company overview
8.8.2. Company snapshot
8.8.3. Operating business segments
8.8.4. Product portfolio
8.8.5. Business performance
8.9. Stanford Chemicals
8.9.1. Company overview
8.9.2. Company snapshot
8.9.3. Operating business segments
8.9.4. Product portfolio
8.10. Sun Pharmaceutical Industries Ltd. (DUSA Pharmaceuticals, Inc.)
8.10.1. Company overview
8.10.2. Company snapshot
8.10.3. Operating business segments
8.10.4. Product portfolio
8.10.5. Business performance
TABLE 01. GLOBAL ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026 ($MILLION)
TABLE 02. FLUOROURACIL ACTINIC KERATOSIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 03. IMIQUIMOD ACTINIC KERATOSIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 04. DICLOFENAC ACTINIC KERATOSIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 05. OTHERS ACTINIC KERATOSIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 06. GLOBAL ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026 ($MILLION)
TABLE 07. PRESCRIPTION ACTINIC KERATOSIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 08. OTC ACTINIC KERATOSIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 09. GLOBAL ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026 ($MILLION)
TABLE 10. ACTINIC KERATOSIS TREATMENT MARKET FOR HOSPITALS PHARMACIES, BY REGION, 2018–2026 ($MILLION)
TABLE 11. ACTINIC KERATOSIS TREATMENT MARKET FOR DRUG STORES AND RETAIL PHARMACIES, BY REGION, 2018–2026 ($MILLION)
TABLE 12. ACTINIC KERATOSIS TREATMENT MARKET FOR ONLINE PROVIDERS, BY REGION, 2018–2026 ($MILLION)
TABLE 13. ACTINIC KERATOSIS TREATMENT MARKET, BY REGION, 2018–2026 ($MILLION)
TABLE 14. NORTH AMERICA ACTINIC KERATOSIS TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 15. U.S. ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 16. U.S. ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 17. U.S. ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 18. CANADA ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 19. CANADA ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 20. CANADA ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 21. MEXICO ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 22. MEXICO ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 23. MEXICO ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 24. NORTH AMERICA ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 25. NORTH AMERICA ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 26. NORTH AMERICA ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 27. EUROPE ACTINIC KERATOSIS TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 28. GERMANY ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 29. GERMANY ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 30. GERMANY ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 31. FRANCE ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 32. FRANCE ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 33. FRANCE ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 34. UK ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 35. UK ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 36. UK ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 37. ITALY ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 38. ITALY ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 39. ITALY ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 40. SPAIN ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 41. SPAIN ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 42. SPAIN ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 43. REST OF EUROPE ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 44. REST OF EUROPE ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 45. REST OF EUROPE ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 46. EUROPE ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 47. EUROPE ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 48. EUROPE ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 49. ASIA-PACIFIC ACTINIC KERATOSIS TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 50. JAPAN ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 51. JAPAN ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 52. JAPAN ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 53. CHINA ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 54. CHINA ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 55. CHINA ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 56. AUSTRALIA ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 57. AUSTRALIA ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 58. AUSTRALIA ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 59. REST OF ASIA-PACIFIC ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 60. REST OF ASIA-PACIFIC ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 61. REST OF ASIA-PACIFIC ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 62. ASIA-PACIFIC ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 63. ASIA-PACIFIC ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 64. ASIA-PACIFIC ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 65. LAMEA ACTINIC KERATOSIS TREATMENT MARKET, BY COUNTRY, 2018–2026 ($MILLION)
TABLE 66. BRAZIL ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 67. BRAZIL ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 68. BRAZIL ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 69. SAUDI ARABIA ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 70. SAUDI ARABIA ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 71. SAUDI ARABIA ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 72. SOUTH AFRICA ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 73. SOUTH AFRICA ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 74. SOUTH AFRICA ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 75. REST OF LAMEA ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 76. REST OF LAMEA ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 77. REST OF LAMEA ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 78. LAMEA ACTINIC KERATOSIS TREATMENT MARKET, BY DRUG TYPE, 2018–2026
TABLE 79. LAMEA ACTINIC KERATOSIS TREATMENT MARKET, BY TYPE, 2018–2026
TABLE 80. LAMEA ACTINIC KERATOSIS TREATMENT MARKET, BY DISTRIBUTION CHANNEL, 2018–2026
TABLE 81. 3M COMPANY: COMPANY SNAPSHOT
TABLE 82. 3M COMPANY: OPERATING SEGMENTS
TABLE 83. 3M COMPANY: PRODUCT PORTFOLIO
TABLE 84. ALMIRALL: COMPANY SNAPSHOT
TABLE 85. ALMIRALL: PRODUCT PORTFOLIO
TABLE 86. BAUSCH HEALTH: COMPANY SNAPSHOT
TABLE 87. BAUSCH HEALTH: OPERATING SEGMENTS
TABLE 88. BAUSCH HEALTH: PRODUCT PORTFOLIO
TABLE 89. BIOFRONTERA: COMPANY SNAPSHOT
TABLE 90. BIOFRONTERA: PRODUCT PORTFOLIO
TABLE 91. HD: COMPANY SNAPSHOT
TABLE 92. HD: PRODUCT PORTFOLIO
TABLE 93. LEO PHARMA: COMPANY SNAPSHOT
TABLE 94. LEO PHARMA: PRODUCT PORTFOLIO
TABLE 95. MYLAN: COMPANY SNAPSHOT
TABLE 96. MYLAN: PRODUCT PORTFOLIO
TABLE 97. NOVARTIS: COMPANY SNAPSHOT
TABLE 98. NOVARTIS: OPERATING SEGMENTS
TABLE 99. NOVARTIS: PRODUCT PORTFOLIO
TABLE 100. STANFORD CHEMICALS: COMPANY SNAPSHOT
TABLE 101. STANFORD CHEMICALS: PRODUCT PORTFOLIO
TABLE 102. SUN PHARMA: COMPANY SNAPSHOT
TABLE 103. SUN PHARMA: OPERATING SEGMENTS
TABLE 104. SUN PHARMA: PRODUCT PORTFOLIO
Similar Reports
Medical implants are permanent devices such as pacemakers or temporary devices such as fracture plates which are removed once their function is completed. These implants are made up of bone, tissue, skin, ceramics, metals, plastics, and other natural materials...
- Publish Date: August 21, 2016
- $5370
Ostomy is a surgery wherein an artificial opening, known as stoma, is created from the colon in the human body to eliminate body wastes such as urine, mucus, and stools, which are collected in artificial bags called ostomy drainage bags. These plastic/rub...
- Publish Date: December 1, 2016
- $5370
Laparoscopy is a minimally invasive procedure used to examine organs inside the abdomen or pelvic cavities by inserting a laparoscope through a small incision in the abdomen. A laparoscope comprises a long, thin tube with high-intensity light, and high-re...
- Publish Date: April 24, 2017
- $5370
